Spyre Therapeutics, Inc.’s SYRE share price has surged by 6.55%, which has investors questioning if this is right time to ...

Fintel reports that on April 8, 2025, Leerink Partners initiated coverage of Spyre Therapeutics (NasdaqGS:SYRE) with a Outperform recommendation. Analyst Price Forecast Suggests 353.70% Upside As of ...

Spyre Therapeutics has a 52 week low of $10.91 and a 52 week high of $40.84. The company has a market cap of $805.64 million, a PE ratio of -1.79 and a beta of 3.05.

WALTHAM, Mass., April 4, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing ...

Spyre Therapeutics (SYRE) announced that it has initiated dosing in a healthy volunteer, Phase 1 clinical trial of its investigational half-life extended anti-IL-23 monoclonal antibody ...

WALTHAM, Mass., March 27, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing ...

As previously reported, Leerink initiated coverage of Spyre Therapeutics (SYRE) with an Outperform rating and $45 price target The firm views Spyre Therapeutics as one of the most compelling ...

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in ...